Stay in the know
Discover the latest financial news and exclusive features from Laidlaw
Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics. Read Article
Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option: Read Article
Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.
Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme demands of nature with the world of fashion and can [...]
Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM). Read Article
Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering
Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo. [...]
Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.
Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc's (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation [...]
Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering
Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.” Link: https://www.meipharma.com/press-releases/mei-pharma-announces-closing-public-offering-common-stock-0
Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.
Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities